These findings highlight the complexity of the CXCL12/CXCR4 axis, which can contribute to disease pathogenesis in SLE and offer therapeutic benefits in T1D, suggesting that blanket targeting of this axis may not be universally beneficial. This evidence concerns the gene CXCR4 and systemic lupus erythematosus.